Forty-five of 431 patients treated with Ixempra in combination with capecitabine were ≥65 years of age and 3 patients were ≥75. Overall, the incidence of grade 3/4 adverse reactions was higher in patients ≥65 years of age versus those <65 years of age (82% versus 68%) including grade 3/4 stomatitis (9% versus 1%), diarrhea (9% versus 6%), palmar-plantar erythrodysesthesia syndrome (27% versus 20%), peripheral neuropathy (24% versus 22%), febrile neutropenia (9% versus 3%), fatigue (16% versus 12%), and asthenia (11 % versus 6%). Toxicity-related deaths occurred in 2 (%) of 43 patients ≥65 years with normal baseline hepatic function or mild impairment.
Due to the possible cholesterol issues, moderate anabolic steroid cycles may be best served with SERM’s in order to protect against estrogenic related side effects. SERM’s will not negatively affect cholesterol; in fact, SERM’s like Nolvadex have been shown to promote healthy cholesterol levels due to their ability to act as estrogen in the liver. However, for many a SERM won’t be enough and AI’s will be necessary. If an AI is necessary, the individual should limit his use and only use as much as is actually needed. Some have suggested that a 10mg per day dosing of Nolvadex along with your Arimidex use may actually aid in cholesterol management.